Home  /  Resource Library  /  Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia

Results of a phase II trial evaluating the combination of ixazomib, dexamethasone, and rituximab for previously untreated Waldenstrom Macroglobulinemia.